Evidence map›Paper›PMID 36091139›Full record

ArticleFrontiers in oncology2022

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial.

Honghai Guo, Ping'an Ding, Chenyu Sun, Peigang Yang, Yuan Tian, Yang Liu, Scott Lowe, Rachel Bentley, Yaru Li, Zhidong Zhang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 6 pooled it
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 6 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Honghai GuoThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Ping'an DingThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Chenyu SunInternal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, Illinois, United States.
Peigang YangThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yuan TianThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yang LiuThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Scott LoweCollege of Osteopathic Medicine, Kansas City University, Kansas City, MO, United States.
Rachel BentleyCollege of Osteopathic Medicine, Kansas City University, Kansas City, MO, United States.
Yaru LiInternal Medicine, Swedish Hospital, Chicago, IL, United States.
Zhidong ZhangThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Dong WangThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yong LiThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Qun ZhaoThe Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hebei Medical University · CNFourth Hospital of Hebei Medical University · CNKansas City University · USSwedish American Hospital · USSaint Joseph Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neoadjuvant chemotherapies have been widely recommended in patients with locally advanced gastric cancer (LAGC). However, the evidence of combining neoadjuvant chemotherapy with anti-programmed death 1 (anti-PD-1) antibody therapy for patients with LAGC is lacking. Thus, we conducted a single-arm phase II trial to evaluate the efficacy and safety of the anti-PD-1 antibody sintilimab plus XELOX regimen (capecitabine plus oxaliplatin) in patients with LAGC. Methods: Patients with LAGC (cT3-4 N+ M0, CY0, P0) were enrolled and received four preoperative cycles of sintilimab (200 mg, IV, Q21d) plus XELOX (oxaliplatin 130 mg/m Results: Thirty patients were enrolled from March 2020 to July 2021, with a median age of 62 years (range, 30-72), and 18 (60.0%) were men. There were 19 (63.3%) patients with PD-L1 CPS ≥1.The pCR rate was 33.3% [95% confidence interval (CI), 17.3%-52.8%], and the major pathologic response (MPR) rate was 63.3% (95% CI, 43.9%-80.1%). All the patients underwent R0 resection. The objective response rate (ORR) and the disease control rate (DCR) were 70.0% (95% CI, 50.6%-85.3%) and 100% (95% CI, 88.4%-100%), respectively. Downstaging of the overall TNM stage was observed in 22 (73.3%) patients. The pCR rate in patients with PD-L1 CPS ≥1 and patients with PD-L1 CPS <1 was 42.1% vs. 18.2% ( Conclusion: Sintilimab plus XELOX as neoadjuvant therapy showed an encouraging pCR rate, MPR rate, and manageable safety. This combination of regimens might provide a new option for patients with LAGC.

Indexed as

immunotherapylocally advanced gastric cancerneoadjuvant regimenphase II trialsintilimab

Identifiers

PMID36091139
PMCPMC9458882
OpenAlexW4293224542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.